Creatine supplements have long been a staple in the fitness community, celebrated for their undeniable ability to enhance muscle strength and athletic performance. However, a recent study reveals that the widely circulated claim regarding creatine's potent anti-inflammatory effects lacks sufficient scientific backing in humans.
A research team led by Professor Vitor Engracia Valenti at São Paulo State University (UNESP) systematically analyzed data from eight randomized controlled human clinical trials. Their findings, published in the international journal Frontiers in Immunology, concluded that there is no consistent evidence showing creatine supplementation meaningfully reduces systemic inflammatory markers in the human body.
Since the 1990s, creatine has been recognized as a highly effective ingredient for increasing training efficiency and building resistance to fatigue. Driven by word-of-mouth claims, its reputation eventually expanded to include purported anti-inflammatory and even anticancer properties, leading manufacturers to add the compound to everything from protein bars to everyday lifestyle drinks. While laboratory cell cultures and animal models have previously demonstrated these anti-inflammatory mechanisms, the researchers emphasized that these outcomes have failed to replicate in clinical trials involving actual human subjects.
In fact, the team's analysis showed that creatine's anti-inflammatory benefits only manifest in highly specific, extreme scenarios. A partial protective effect against acute inflammatory responses was observed exclusively when elite endurance athletes—such as triathletes or long-distance runners—consumed short-term, mega-doses of the supplement (approximately 20 grams per day for five days).
These protective effects did not carry over to other demographics. In clinical trials evaluating older adults or individuals suffering from osteoarthritis, several weeks of creatine supplementation failed to produce any statistically or clinically significant drops in key inflammatory markers, such as C-reactive protein (CRP) and interleukins. The average reduction in CRP was a negligible 0.41 mg/dL, with an even smaller decrease observed in interleukin-6. The research team noted that any minor improvements observed in these groups were far more likely driven by the physiological benefits of the exercise itself rather than the supplement.
Furthermore, Professor Valenti noted that inflammation triggered during exercise is not inherently detrimental. Temporary spikes in acute inflammatory molecules actually interact with other exercise-induced physiological signals to assist with vital muscle recovery, tissue remodeling, and athletic adaptation.
On a positive note, the study firmly reaffirmed creatine's exceptional safety profile. Across all evaluated demographics—ranging from high-intensity athletes to older individuals and osteoarthritis patients—both short-term and long-term creatine use produced no serious side effects or metabolic abnormalities, such as muscle cramps, dehydration, or gastrointestinal distress.
